Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_238fb880caf3cb29e2033ad67054bf0f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
filingDate |
2016-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5072db15e2ac0dc626b0c6070312f2e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8401de67fbc9e5c8361674567e0492eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ae079285cc5093630c92a1ca0aecb13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1c41fb08d775f3ef30330c093073fe8 |
publicationDate |
2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019134091-A1 |
titleOfInvention |
Method to Treat Cancer with Engineered T-Cells |
abstract |
Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018318444-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021042072-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113481165-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110996974-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11453712-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11325948-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208455-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11066479-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021191871-A1 |
priorityDate |
2015-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |